| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
| Net loss | -4,281 | -22,804 | -34,881 |
| Depreciation and amortization | 17,738 | 17,987 | 60,274 |
| Amortization of deferred financing costs | NaN | NaN | 3,035 |
| Amortization of deferred financing costs and mortgage discounts (premiums) | 1,044 | 4,753 | NaN |
| Accretion of terminated swap | -1,476 | -344 | 0 |
| Amortization of mortgage premiums and discounts, net | NaN | NaN | 65 |
| (accretion) amortization of market lease and other intangibles, net | -147 | -131 | 2,022 |
| Bad debt expense | NaN | NaN | 659 |
| Stock-based compensation amortization expense | 612 | 1,863 | 1,903 |
| (gain) loss on sale of real estate investments | NaN | -467 | 28,267 |
| Gain on extinguishment of debt | NaN | 0 | 257 |
| Loss (gain) on non-designated derivative instruments | NaN | -26 | -46 |
| Gain on sale of real estate investments | 0 | NaN | NaN |
| Cash received from non-designated derivative instruments | 375 | 683 | 2,609 |
| Loss on non-designated derivative instruments | -87 | NaN | NaN |
| Impairment charges | 0 | 11,162 | 33,752 |
| Deferred tax valuation allowance | 79 | -496 | -1,215 |
| Straight-line rent receivable, net | 268 | -3,767 | 2,412 |
| Prepaid expenses and other assets, net | -597 | -10,847 | 7,155 |
| Termination fees payable to related parties | NaN | NaN | 0 |
| Accounts receivable, net | -59 | 7,790 | -4,391 |
| Accounts payable, accrued expenses and other liabilities | -2,188 | -5,382 | -35,838 |
| Deferred leasing costs | 738 | 899 | 7,182 |
| Deferred rent | -2,322 | -983 | 3,013 |
| Net cash provided by (used in) operating activities | 9,013 | 9,959 | -3,008 |
| Acquisitions of real estate | NaN | 0 | 250 |
| Capital expenditures | 5,265 | 11,773 | 16,953 |
| Investments in non-designated interest rate caps, net | 154 | 1,379 | 0 |
| Proceeds from sales of real estate, net | 0 | 9,821 | 90,340 |
| Net cash (used in) provided by investing activities | -5,419 | -3,331 | 73,137 |
| Borrowings/proceeds from credit facility-Credit Agreement | NaN | 336,000 | NaN |
| Borrowings/proceeds from credit facility-Fannie Mae Secured Debt | NaN | 0 | NaN |
| Repayments of fannie mae secured debt | 1,442 | 1,442 | 26,034 |
| Proceeds from fannie mae and other secured debt | NaN | NaN | 0 |
| Proceeds from mortgage notes payable | NaN | 0 | NaN |
| Repayments of mortgage notes payable | 221 | 330,468 | 645 |
| Proceeds from interest rate swap terminations | 0 | 8,259 | NaN |
| Payments of deferred financing costs | NaN | 6,006 | 205 |
| Proceeds from promissory note | NaN | 0 | 0 |
| Taxes paid for net settlement of equity-based awards | 444 | 612 | NaN |
| Repurchase of preferred stock | NaN | 920 | 4,503 |
| Payment of offering costs | NaN | 1,217 | NaN |
| Purchase of non-controlling interest | NaN | 978 | NaN |
| Distributions paid on preferred stock-Series ACumulative Redeemable Perpetual Preferred Stock | 1,773 | 1,771 | 5,410 |
| Contributions from non-controlling interest holders | NaN | 0 | NaN |
| Distributions paid on preferred stock-Series BCumulative Redeemable Perpetual Preferred Stock | 1,521 | 1,512 | 4,752 |
| Distributions to non-controlling interest holders | 46 | 45 | 139 |
| Net cash used in financing activities | -5,447 | -712 | -41,688 |
| Net change in cash, cash equivalents and restricted cash | -1,853 | 5,916 | 28,441 |
| Cash, cash equivalents and restricted cash, beginning of period | 102,536 | NaN | 74,095 |
| Cash, cash equivalents and restricted cash, end of period | 106,599 | NaN | 102,536 |
National Healthcare Properties, Inc. (NHPBP)
National Healthcare Properties, Inc. (NHPBP)